โ Home
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights (2) ๐ข Company Q&A (574) ๐ ๏ธ Industry Q&A (121) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
| Date | Press release |
|---|---|
| 2026-03-28 15:00:00 | Takedaโs Zasocitinib Delivered Rapid And Durable Skin Clearance In A Convenient Once-daily Pill, Affirming Promise To Reshape Psoriasis Care Osaka, japan & cambridge, mass.--(business wire)--takedaโs zasocitinib delivered rapid and durable skin clearance in a convenient once-daily pill, affirming promise to reshape psoriasis care. |
| 2026-03-02 02:00:00 | Takeda And Protagonist Announce U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Rusfertide As A Potential First-in-class Therapy For Polycythemia Vera Osaka, japan & cambridge, mass. & newark, calif.--(business wire)--takeda (tse:4502/nyse:tak) and protagonist therapeutics, inc. (โprotagonistโ) (nasdaq:ptgx) today announced that the u.s. food and drug administration (fda) accepted the new drug application (nda) and granted priority review for rusfertide. rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (pv). the fda has set a prescription drug user fee act. |
| 2026-02-19 12:00:00 | Positive Phase 3 Data Demonstrate Potential For Entyvioยฎ (vedolizumab) To Address Treatment Gap For Children And Adolescents With Moderate To Severe Ulcerative Colitis Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced positive data from the pivotal phase 3 kepler trial, which demonstrated that entyvioยฎ (vedolizumab) can offer the possibility of clinical remission for patients ages 2 and older with moderately to severely active ulcerative colitis (uc), a chronic inflammatory disease of the gastrointestinal tract and one of the two most common types of inflammatory bowel disease.1,2 the results, presented at the 21st c. |
| 2026-02-10 03:15:00 | U.s. Food And Drug Administration Accepts New Drug Application And Grants Priority Review For Takedaโs Oveporexton (tak-861) As A Potential First-in-class Therapy For Narcolepsy Type 1 Osaka, japan & cambridge, mass.--(business wire)--fda accepts new drug application and grants priority review for takedaโs oveporexton as a potential first-in-class therapy for narcolepsy type 1. |
| 2026-02-09 08:00:00 | Iambic Announces Collaboration With Takeda To Advance Ai-driven Design Of Small Molecules San diego & cambridge, mass.--(business wire)--iambic, a clinical-stage life science and technology company developing novel medicines using its ai-driven discovery and development platform, today announced a multi-year technology and discovery collaboration agreement with takeda that will use iambicโs industry leading ai drug discovery models to advance a select set of high-priority small molecule programs, initially in takedaโs oncology and gastrointestinal and inflammation therapeutic areas. |
| 2026-01-29 01:37:00 |
|
| 2026-01-05 07:00:00 |
|
| 2025-12-18 03:00:00 |
|
| 2025-12-06 09:30:00 |
|
| 2025-11-19 06:30:00 |
|
| 2025-11-07 11:00:00 |
|
| 2025-10-30 03:04:00 |
|
| 2025-10-21 20:25:00 |
|
| 2025-10-14 05:00:00 |
|
| 2025-09-23 18:04:00 |
|
๐ฐ Browse additional press releases for Takeda Pharmaceutical!
Sign up for free or log in๐ Unlock our free guide: "The Checklist Value Investor โ A Smarter Way to Pick Stocks"